Q-omics provides the consensus-scored MIR429 profile across patient tissues and cancer cell-line models. MIR429 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR429 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MIR429 RNA expression shows 15,510 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where MIR429 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR429 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR429 survival associations across molecular data types. MIR429 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR429 RNA expression–survival associations across cancer types. High MIR429 expression shows unfavorable associations in LGG, CESC and KIRC, but favorable associations in HNSC, BLCA and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR429 RNA expression.
This table summarizes MIR429 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR429. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR429 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in COAD, STAD and CHOL. The KIRC box plot shows higher MIR429 RNA expression in normal versus tumor tissue (log2 FC = −1.051, t-test p < 0.001).
This table shows molecular features associated with MIR429 in patient tissues and cancer cell lines. In patient samples, MIR429 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MIR429 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
